"The panel made a “conditional” recommendation for the monoclonal antibody sotrovimab to treat people who do not have severe COVID-19 but are at high risk of hospitalization.
...The trial found a substantial reduction in hospitalization among individuals at high risk, but “trivial” benefits among people at lower risk.
However, the trial finished before the Omicron variant emerged.
The panel reports that laboratory experiments suggest that sotrovimab can neutralize the new variant but that higher concentrations are required than with the previous variants.
The living guideline already contained a conditional recommendation for using a combination of two other monoclonal antibodies, casirivimab and imdevimab."
Well there’s another medication that will be banned.
We have been using baricitinib for the last six months.
no mention of Viagra?
Nac?
I wouldn’t trust one thing these criminals recommend....
BAN World Health Organization FROM FACEBOOK AND TWITTER!
DANGEROUS MISINFORMATION WILL KILL PEOPLE!
DIE! DIE!, Die, Die, die, die...everybodies going to ...
ayieeee...
Of Course HCQ is also used for bad arthritis. Gee I wonder.
Sounds reasonable to me.
They hit me with two shots of Remdesevir, and I’m fine.
Eli Lilly wants in on the COVID game. And yet neither out-of-patent HCQ nor out-of-patent ivermectin are to be allowed to the plebes.
Eli Lilly has sued in Dehli High Court for patent infringement against some Indian companies.
One reads "In this case, MSF pointed out that in many countries baricitinib is under patent of the American company Eli Lilly, which sells it at a price close to $2,000 dollars, and that this could affect the use of this drug for the treatment of patients in countries with fewer resources. “In countries like Bangladesh or India a generic version of this drug can be obtained for less than $6, but in many countries generic baricitinib is not available because it is under a patent monopoly with Eli Lilly, a company that has applied for and obtained patents in many places, including countries hard hit by the pandemic, such as Brazil, South Africa, Indonesia and Russia,” the organization added.>
Source: https://digismak.com/who-authorized-the-drugs-baricitinib-and-sotrovimab-to-treat-covid/
The $6 price tag for generic manufacturers being sued in various countries, gives an idea about the Eli Lilly pricing of an existing drug versus its cost to manufacture.
The game is one of massive profitability.
What’s wrong with diphenhydramine...